Deepa Jagadeesh

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Molecularly Imprinted

Multiple Myeloma

Chronic Lymphocytic Leukemia

Top Venues

Leukemia & lymphoma

This page only lists publications with an associated author ORCID identifier.

Publications

Brian T Hill, Yanwen Chen, Deepa Jagadeesh, Robert M Dean, Omer Koc, Kirsten Boughan, Brenda W Cooper, Brad Pohlman, Paolo F Caimi, Mitchell Reed Smith
Lenalidomide, rituximab (R 2 ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma. Leukemia & lymphoma 65 (6) (2024)
Brian T Hill, Yanwen Chen, Deepa Jagadeesh, Robert M Dean, Omer Koc, Kirsten Boughan, Brenda W Cooper, Brad Pohlman, Paolo F Caimi, Mitchell Reed Smith
Lenalidomide, rituximab (R 2 ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma. Leukemia & lymphoma 65 (6) (2024)
Brian T Hill, Yanwen Chen, Deepa Jagadeesh, Robert M Dean, Omer Koc, Kirsten Boughan, Brenda W Cooper, Brad Pohlman, Paolo F Caimi, Mitchell Reed Smith
Lenalidomide, rituximab (R 2 ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma. Leukemia & lymphoma (2024)
Brian T Hill, Yanwen Chen, Deepa Jagadeesh, Robert M Dean, Omer Koc, Kirsten Boughan, Brenda W Cooper, Brad Pohlman, Paolo F Caimi, Mitchell Reed Smith
Lenalidomide, rituximab (R 2 ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma. Leukemia & lymphoma 65 (6) (2024)
Deepa Jagadeesh, Steve Horwitz, Nancy L Bartlett, Youn Kim, Eric Jacobsen, Madeleine Duvic, Meredith Little, William Trepicchio, Keenan Fenton, Matthew Onsum, Julie Lisano, Ranjana Advani
Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma. The oncologist 27 (10) (2022)